Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren + Ivacaftor N-of-1 in Nonsense Mutation CF
NCT03256968Phase 4Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ataluren in cystic fibrosis (CF), sponsored by University of Alabama at Birmingham. Primary endpoint: Forced Expiratory Volume in 1 Second at 1 year. Started Jan 2017; status: completed.
02
Drugs
ataluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03256968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256968.